AR039718A1 - Derivados de indol utiles como antagonistas de la histamina h3 - Google Patents
Derivados de indol utiles como antagonistas de la histamina h3Info
- Publication number
- AR039718A1 AR039718A1 ARP030102203A ARP030102203A AR039718A1 AR 039718 A1 AR039718 A1 AR 039718A1 AR P030102203 A ARP030102203 A AR P030102203A AR P030102203 A ARP030102203 A AR P030102203A AR 039718 A1 AR039718 A1 AR 039718A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- independently selected
- alkoxy
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto representando por la fórmula estructural (1) o una sal o solvato farmacéuticamente aceptable del mismo, en el cual a es de 0 a 3; b es de 0 a 3; n es 1, 2, ó 3; p es 1, 2 ó 3; r es 0, 1, 2 ó 3; X es un enlace o alquileno C1-6; M1 es CH o N; M2 es C(R3) o N; con las salvedades de que cuando M2 es N; p no es 1; y que cuando r es o, M2 es C(R3) y que la suma de p y r es de 1 a 4; Y es -C(=O)-, -C(=S)-, -(CH2)Q-, -C(=O)NR4-, -C(=O)CH2-, -SO1-2-, -C(=N-CN)-NH- o -NH-C(=N-CN)-; con las salvedades de que, cuando M1 es N, Y no es -NR4C(=O)- ni -NH-C(=N-CN)- y cuando M2 es N, Y no es -C(=O)NR4- ni -C(=N-CN)-NH-; q es 1 a 5, siempre que, cuando tanto M1 como M2 son ambos N, q no sea 1; Z es un enlace, alquileno C1-6, alquenileno C2-6, -C(=O)-, -CH(CN)- o -CH2C(=O)NR4-; R1 es un resto seleccionado del grupo de fórmulas (2); Q es -N(R8)-, -S- o -O-; k es 0, 1, 2, 3 ó 4; k1 es 0, 1, 2 ó 3; k2 es 0, 1 ó 2; la línea de puntos representa un enlace doble optativo; R y R7 son independientemente seleccionados entre el grupo que consiste en H, alquilo C1-6, haloalquilo (C1-6), alcoxi C1-6, alcoxi(C1-6)-alquilo(C1-6)-, alcoxi(C1-6)-alcoxi(C1-6)-, alcoxi(C1-6)-alquilo(C1-6)-SO0-2, R32-arilalcoxi (C1-6)-, R32-arilalquilo (C1-6)-, R32-arilo, R32-ariloxi, R32-heteroarilo, cicloalquilo (C1-6), cicloalquil(C3-6)-alquilo(C1-6), cicloalquil(C3-6)-alcoxi(C1-6), cicloalquil(C3-6)-oxi, R37-heterocicloalquilo, N(R30)(R31)-alquilo (C1-6), N(R30)(R31), -NH-alquil(C1-6)-O-alquilo(C1-6), -NHC(O)NH(R29); R22-S(O)0-2-, haloalquil(C1-6)-S(O)0-2-, N(R30)(R31)-alquilo(C1-6)-S(O)0-2-, benzoilo, alcoxi(C1-6)-carbonilo, R37-heterocicloalquil-N(R29)-C(O)-, alquil(C1-6)-N(R29)-C(O)-, alquil(C1-6)-N(alcoxiC1-6)-C(O)-, -C(=NOR36)R36 y -NHC(O)R29 y, cuando no está presente el enlace doble optativo, R7 puede ser OH; R8 es H, alquilo C1-6, halo-alquilo (C1-6), alcoxi(C1-6)-alquilo(C2-6)-, R32-aril-alquilo (C1-6)-, R32-arilo, R32-heteroarilo, R32-heteroaril-alquilo (C1-6)-, cicloalquilo (C3-6), cicloalquil(C3-6)-alquilo(C1-6), R37-heterocicloalquilo, R37-heterocicloalquil-alquilo (C1-6), N(R30)(R31)-alquilo (C2-6)-, R22-S(O)2-, halo-alquilo (C1-6)-S(O)2-, R22-S(O)0-1-alquilo (C2-6)-, halo-alquil(C1-6)-S(O)0-1-alquilo(C2-6)-, alquil(C1-6)-N(R29)-SO2- o R32-heteroaril-SO2; R2 es un anillo de heteroarilo de seis miembros que tiene 1 ó 2 heteroátomos independientemente seleccionados entre N o N-O, siendo los restantes átomos del anillo, de carbono; un anillo de heteroarilo de cinco miembros con 1, 2, 3 ó 4 heteroátomos independientemente seleccionados entre N, O ó S, donde los restantes átomos del anillo de carbono, R32-quinolilo, R32-arilo, un resto de fórmula (3); o heterocicloalquilo; donde dicho anillo de heteroarilo de seis miembros o dicho anillo de heteroarilo de cinco miembros está optativamente sustituidos con R6; R3 es H, halógeno, alquilo C1-6, -OH o alcoxi (C1-6), R4 es independientemente seleccionado entre el grupo que consiste en hidrógeno, alquilo C1-6, cicloalquilo C3-6, cicloalquil(C3-6)-alquilo(C1-6), R33-arilo, R33-aril-alquilo (C1-6) y R32-heteroarilo; R5 es hidrógeno, alquilo C1-6; -C(O)R20, -C(O)2R20, -C(O)N(R20)2, R33-aril-alquilo (C1-6) o alquil(C1-6)-SO2-; R6 representa 1 a 3 sustituyentes independientemente seleccionados entre el grupo que consiste en -OH, halógeno, alquilo C1-6, alcoxi C1-6, -CF3, -NR4R5, -alquil(C1-6)-NR4R5, fenilo, R33-fenilo, NO2, -CO2R4, -CON(R4)2, -NHC(O)N(R4)2, R32-heteroaril-SO2-NH-, R32-aril-alquil(C1-6)-NH, R32-heteroaril-alquilo(C1-6)-NH-, R32-heteroaril-NH-C(O)-NH-, R37-heterocicloalquil-N(R29)-C(O)- y R37-heterocicloalquil-N(R29)-C(O)-NH; R12 es independientemente seleccionado entre el grupo que consiste en alquilo C1-6, hidroxilo, alcoxi C1-6 o flúor, siempre que, cuando R12 es hidroxi o flúor, luego R12 no esté unido a un carbono adyacente a un nitrógeno o R12 forme un puente de alquilo C1-2 desde un carbono del anillo hasta otro carbono del anillo; R13 es independientemente seleccionado entre el grupo que consiste en alquilo C1-6, hidroxilo, alcoxi C1-6 o flúor, siempre que, cuando R13 es hidroxi o flúor, luego R13 no esté unido a un carbono adyacente a un nitrógeno o forme un puente de alquilo C1-2 desde un carbono del anillo hasta otro carbono del anillo; o R13 es =O; R20 es independientemente seleccionado entre el grupo que consiste en hidrógeno, alquilo C1-6, o arilo, donde dicho grupo arilo está optativamente sustituido con 1 a 3 grupos independientemente seleccionados entre halógeno, -CF3, -OCF3-, hidroxilo o metoxi o, cuando hay dos grupos R20 presentes, dichos dos grupos R20 tomados junto con el nitrógeno al cual están unidos, forman un anillo heterocíclico de cinco o seis miembros; R22 es alquilo C1-6, R34-arilo o heterocicloalquilo; R24 es H, alquilo C1-6, -SO2R22 o R34-arilo; R25 es independientemente seleccionado entre el grupo que consiste en alquilo C1-6, halógeno, CN, -CF3, -OH, alcoxi C1-6, alquil(C1-6)-C(O)-, aril-C(O)-, N(R4)(R5)-C(O)-, N(R4)(R5)-S(O)1-2-, halo-alquilo (C1-6)- o halo-alcoxi(C1-6)-alquilo(C1-6)-; R29 es H, alquilo C1-6, R35-arilo o R35-aril-alquilo (C1-6)-; R30 es H, alquilo C1-6-, R35-arilo o R35-aril-alquilo (C1-6)-; R31 es H, alquilo C1-6, R35-arilo, R35-aril-alquilo (C1-6)-; alquil(C1-6)-C(O)-, R35-aril-C(O)-, N(R4)(R5)-C(O)-, alquil(C1-6)-S(O)2- o R35-aril-S(O)2-; o R30 y R31, juntos son -(CH2)4-5-, -(CH2)2-O-(CH2)2- o -(CH2)2-N(R29)-(CH2)2- y forman un anillo con el nitrógeno al cual están unidos; R32 representa 1 a 3 sustituyentes independientemente seleccionados entre el grupo que consiste en H, -OH, halógeno, alquilo C1-6, alcoxi C1-6, R35-aril-O-, SR22, -CF3, -OCF3, -OCHF2, -NR4R5, fenilo, R33-fenilo, -NO2, -CO2R4, -CON(R4)2, -S(O)2R22, -S(O)2N(R20)2, -N(R24)S(O)2R22, -CN, hidroxi-alquilo (C1-6)-, -OCH2CH2OR22 y R35-aril-alquil(C1-6)-O-, donde dicho grupo arilo está optativamente sustituido con 1 a 3 halógenos independientemente seleccionados; R33 representa 1 a 3 sustituyentes independientemente seleccionados entre el grupo que consiste en alquilo C1-6, halógeno, -CN, -NO2, -OCHF2 y O-alquilo (C1-6)-; R34 representa 1 a 3 sustituyentes independientemente seleccionados entre el grupo que consiste en H, halógeno, -CF3, -OCF3, -OH y -OCH3; R35 representa 1 a 3 sustituyentes independientemente seleccionados entre el grupo que consiste en hidrógeno, halo, alquilo C1-6, hidroxi, alcoxi C1-6, fenoxi, -CF3, -N(R36)2, -COOR20 y -NO2; R36 es independientemente seleccionado entre el grupo que consiste en H y alquilo C1-6; y R37 es independientemente seleccionado entre el grupo que consiste en H, alquilo C1-6 y alcoxicarbonilo (C1-6). Reivindicación 13: Una composición farmacéutica que comprende una cantidad efectiva de un compuesto de acuerdo con la reivindicación 1 y un vehículo farmacéuticamente aceptable. Reivindicación 14: El uso de un compuesto de acuerdo con la reivindicación 1 para la preparación de un medicamento para el tratamiento de alergia, respuestas de las vías respiratorias inducidas por alergia, congestión, hipotensión, enfermedad cardiovascular, enfermedades del tracto GI, híper e hipomotilidad y secreción ácida del tracto gastrointestinal, obesidad, trastornos del sueno, perturbaciones del sistema nervioso central, trastorno de hiperactividad y déficit de la atención, hipo e hiperactividad del sistema nervioso central, enfermedad de Alzheimer, esquizofrenia y migrana. Reivindicación 15: Una composición farmacéutica que comprende una cantidad efectiva de un compuesto de acuerdo con al reivindicación 1, y una cantidad efectiva de un antagonista del receptor H1 y un vehículo farmacéuticamente aceptable. Reivindicación 16: El uso de un compuesto de acuerdo con la reivindicación para la preparación de un medicamento para usar en combinación con un antagonista del receptor H1 para el tratamiento de alergia, respuestas de las vías respiratorias inducidas por alergias y congestión.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39098702P | 2002-06-24 | 2002-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039718A1 true AR039718A1 (es) | 2005-03-09 |
Family
ID=30000654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030102203A AR039718A1 (es) | 2002-06-24 | 2003-06-20 | Derivados de indol utiles como antagonistas de la histamina h3 |
Country Status (22)
Country | Link |
---|---|
US (1) | US6951871B2 (es) |
EP (2) | EP1777223A1 (es) |
JP (1) | JP4326468B2 (es) |
KR (1) | KR20050009757A (es) |
CN (1) | CN100497334C (es) |
AR (1) | AR039718A1 (es) |
AT (1) | ATE344798T1 (es) |
AU (1) | AU2003243709B2 (es) |
CA (1) | CA2489337C (es) |
CY (1) | CY1105986T1 (es) |
DE (1) | DE60309598T2 (es) |
DK (1) | DK1539742T3 (es) |
ES (1) | ES2271644T3 (es) |
HK (1) | HK1072259A1 (es) |
IL (1) | IL165863A0 (es) |
MX (1) | MXPA05000193A (es) |
MY (1) | MY135686A (es) |
NZ (1) | NZ537200A (es) |
PT (1) | PT1539742E (es) |
TW (1) | TW200400031A (es) |
WO (1) | WO2004000831A1 (es) |
ZA (1) | ZA200410213B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
JP4621502B2 (ja) * | 2002-06-28 | 2011-01-26 | ユーロ−セルティーク エス.エイ. | 疼痛の治療に有用な治療剤 |
WO2004064730A2 (en) | 2003-01-14 | 2004-08-05 | Cytokinetics, Inc. | Compounds, compositions and methods |
TWI359812B (en) | 2004-06-17 | 2012-03-11 | Cytokinetics Inc | Compounds, compositions and methods |
WO2005123716A1 (en) * | 2004-06-21 | 2005-12-29 | F. Hoffmann-La Roche Ag | Indole derivatives as histamine receptor antagonists |
US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
FR2878849B1 (fr) * | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
EA012613B1 (ru) * | 2004-12-06 | 2009-10-30 | Авентис Фарма С.А. | Замещённые индолы, содержащие их композиции, способ получения и применение |
BRPI0606502A2 (pt) | 2005-01-19 | 2009-06-30 | Hoffmann La Roche | compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento ou prevenção de doenças que são associadas com a modulação de receptores h3; método para o tratamento ou prevenção de obesidade em um ser humano ou animal; método de tratamento ou prevenção de diabetes tipo ii em um ser humano ou animal e usos de compostos |
ES2337728T3 (es) | 2005-06-20 | 2010-04-28 | Schering Corporation | Piperidinas sustituidas unidas a carbono y sus derivados utiles como antagonistas de histamina h3. |
WO2007001975A1 (en) * | 2005-06-20 | 2007-01-04 | Schering Corporation | Piperidine derivatives useful as histamine h3 antagonists |
WO2007016496A2 (en) * | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
CA2623025A1 (en) | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
RU2417226C2 (ru) * | 2005-11-18 | 2011-04-27 | Ф.Хоффманн-Ля Рош Аг | Производные азаиндол-2-карбоксамида |
BRPI0619233A2 (pt) * | 2005-11-30 | 2011-09-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal |
TW200808321A (en) * | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
JP5178526B2 (ja) | 2005-12-19 | 2013-04-10 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
CN101426777A (zh) * | 2005-12-21 | 2009-05-06 | 先灵公司 | 用作组胺h3拮抗剂的苯氧基哌啶及其类似物 |
US20070142369A1 (en) * | 2005-12-21 | 2007-06-21 | Margaret Van Heek | Combination of an H3 antagonist/inverse agonist and an appetite suppressant |
PE20071136A1 (es) * | 2005-12-21 | 2007-12-29 | Schering Corp | Derivados de anilina sustituida como antagonistas de la histamina h3 |
CA2637531A1 (en) * | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
US7514433B2 (en) * | 2006-08-03 | 2009-04-07 | Hoffmann-La Roche Inc. | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives |
CA2667548C (en) * | 2006-10-27 | 2015-02-03 | Boehringer Ingelheim International Gmbh | Substituted piperidyl-propane-thiols |
JP5581055B2 (ja) * | 2006-10-27 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピペリジル−プロパン−チオールccr3モジュレーター |
US20090069337A1 (en) * | 2007-08-15 | 2009-03-12 | Memory Pharmaceuticals Corporation | 3' substituted compounds having 5-ht6 receptor affinity |
WO2009089134A1 (en) * | 2008-01-04 | 2009-07-16 | Src, Inc. | Methods for measuring a patint response upon administration of a drug and compositions thereof |
KR20160129109A (ko) | 2008-05-23 | 2016-11-08 | 아미라 파마슈티칼스 인코포레이티드 | 5-리폭시게나아제 활성화 단백질 억제제 |
US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
US20100035862A1 (en) * | 2008-06-25 | 2010-02-11 | Abbott Laboratories | Novel aza-cyclic indole-2-carboxamides and methods of use thereof |
AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
WO2010011657A1 (en) * | 2008-07-23 | 2010-01-28 | Schering Corporation | Bicyclic heterocycle derivatives as histamine h3 receptor antagonists |
US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
EP2556068B1 (en) | 2010-04-08 | 2019-01-23 | Respivert Limited | P38 map kinase inhibitors |
WO2011153359A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Fxr有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
EP3797769A1 (fr) | 2019-09-25 | 2021-03-31 | Fontès, M. Michel | Composition a usage therapeutique |
CA3124579A1 (en) | 2020-07-15 | 2022-01-15 | Schabar Research Associates Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
AU2021310264A1 (en) | 2020-07-15 | 2023-02-09 | Schabar Research Associates Llc | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0730037B2 (ja) | 1987-03-13 | 1995-04-05 | 第一製薬株式会社 | ピリミジニルプロピオン酸誘導体 |
DK181190D0 (da) | 1990-07-30 | 1990-07-30 | Lundbeck & Co As H | 3-aryl-indol- eller 3-aryl-indazolderivater |
US5217986A (en) * | 1992-03-26 | 1993-06-08 | Harbor Branch Oceanographic Institution, Inc. | Anti-allergy agent |
US5352707A (en) * | 1992-03-26 | 1994-10-04 | Harbor Branch Oceanographic Institution, Inc. | Method for treating airway congestion |
US5846982A (en) | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
EP0920315B1 (en) | 1996-08-16 | 2005-12-28 | Schering Corporation | Treatment of upper airway allergic responses with a combination of histamine receptor antagonists |
ATE275142T1 (de) * | 1996-11-25 | 2004-09-15 | Procter & Gamble | 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten |
US5869479A (en) | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
DE60026581T2 (de) | 1999-12-20 | 2006-12-28 | Eli Lilly And Co., Indianapolis | Indolderivate zur behandlung von depression und angstzuständen |
PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
ES2172436B1 (es) | 2000-10-31 | 2004-01-16 | Almirall Prodesfarma Sa | Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
EP1408965A2 (en) * | 2001-02-08 | 2004-04-21 | Schering Corporation | Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders |
AU2002244271A1 (en) * | 2001-03-13 | 2002-09-24 | Pharmacopeia, Inc. | Non-imidazole compounds as histamine h3 antagonists |
-
2003
- 2003-06-20 MY MYPI20032323A patent/MY135686A/en unknown
- 2003-06-20 ES ES03761216T patent/ES2271644T3/es not_active Expired - Lifetime
- 2003-06-20 WO PCT/US2003/019619 patent/WO2004000831A1/en active IP Right Grant
- 2003-06-20 EP EP06020215A patent/EP1777223A1/en not_active Withdrawn
- 2003-06-20 IL IL16586303A patent/IL165863A0/xx unknown
- 2003-06-20 MX MXPA05000193A patent/MXPA05000193A/es active IP Right Grant
- 2003-06-20 DK DK03761216T patent/DK1539742T3/da active
- 2003-06-20 AR ARP030102203A patent/AR039718A1/es unknown
- 2003-06-20 CN CNB038147173A patent/CN100497334C/zh not_active Expired - Fee Related
- 2003-06-20 DE DE60309598T patent/DE60309598T2/de not_active Expired - Lifetime
- 2003-06-20 KR KR10-2004-7020914A patent/KR20050009757A/ko not_active Application Discontinuation
- 2003-06-20 US US10/600,674 patent/US6951871B2/en not_active Expired - Fee Related
- 2003-06-20 CA CA2489337A patent/CA2489337C/en not_active Expired - Fee Related
- 2003-06-20 AU AU2003243709A patent/AU2003243709B2/en not_active Ceased
- 2003-06-20 EP EP03761216A patent/EP1539742B1/en not_active Expired - Lifetime
- 2003-06-20 JP JP2004516072A patent/JP4326468B2/ja not_active Expired - Fee Related
- 2003-06-20 PT PT03761216T patent/PT1539742E/pt unknown
- 2003-06-20 TW TW092116874A patent/TW200400031A/zh unknown
- 2003-06-20 NZ NZ537200A patent/NZ537200A/en unknown
- 2003-06-20 AT AT03761216T patent/ATE344798T1/de not_active IP Right Cessation
-
2004
- 2004-12-17 ZA ZA200410213A patent/ZA200410213B/en unknown
-
2005
- 2005-06-18 HK HK05105092A patent/HK1072259A1/xx not_active IP Right Cessation
-
2007
- 2007-02-05 CY CY20071100153T patent/CY1105986T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1539742A1 (en) | 2005-06-15 |
DK1539742T3 (da) | 2006-12-27 |
ATE344798T1 (de) | 2006-11-15 |
ZA200410213B (en) | 2005-10-20 |
TW200400031A (en) | 2004-01-01 |
US6951871B2 (en) | 2005-10-04 |
MXPA05000193A (es) | 2005-04-08 |
EP1777223A1 (en) | 2007-04-25 |
DE60309598D1 (de) | 2006-12-21 |
WO2004000831A1 (en) | 2003-12-31 |
ES2271644T3 (es) | 2007-04-16 |
IL165863A0 (en) | 2006-01-15 |
AU2003243709B2 (en) | 2007-01-18 |
CA2489337C (en) | 2010-05-25 |
CN100497334C (zh) | 2009-06-10 |
JP4326468B2 (ja) | 2009-09-09 |
MY135686A (en) | 2008-06-30 |
JP2005531615A (ja) | 2005-10-20 |
CN1662524A (zh) | 2005-08-31 |
NZ537200A (en) | 2007-09-28 |
AU2003243709A1 (en) | 2004-01-06 |
CY1105986T1 (el) | 2011-04-06 |
CA2489337A1 (en) | 2003-12-31 |
EP1539742B1 (en) | 2006-11-08 |
HK1072259A1 (en) | 2005-08-19 |
KR20050009757A (ko) | 2005-01-25 |
US20040019099A1 (en) | 2004-01-29 |
PT1539742E (pt) | 2007-01-31 |
DE60309598T2 (de) | 2007-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039718A1 (es) | Derivados de indol utiles como antagonistas de la histamina h3 | |
AR040405A1 (es) | Derivados de bencimidazol utiles como antagonistas de histamina h3 | |
AR040406A1 (es) | Antagonistas de histamina h3 de benzimidazolona | |
AR065495A1 (es) | Metodos para usar derivados de bencimidazol para tratar o prevenir dolor, diabetes, complicacion diabetica composiciones. | |
RU2381224C2 (ru) | Пиперидинаминобензимидазольные производные как ингибиторы репликации респираторного синцитиального вируса | |
ES2345640T3 (es) | Compuestos de bifenilo utiles en la sintesis de antagonistas del receptor muscarinico. | |
ES2501544T3 (es) | Agentes antihelmínticos y su uso | |
PE20060497A1 (es) | Aminas policiclicas sustituidas con arilo como antagonistas de mch | |
NO20082000L (no) | Pyrimidinamidforbindelser som PGDS-inhibitorer | |
AR035440A1 (es) | Compuestos antagonistas del receptor h3, el uso de los mismos solos o en combinacion para la manufactura de medicamentos y composiciones farmaceuticas | |
NO331165B1 (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter | |
DE602005016261D1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
NO20063748L (no) | Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer | |
CA2551508A1 (en) | Novel quinoline derivatives | |
RS53682B1 (en) | PIRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASE | |
AR074814A1 (es) | Pirimidinas sustituidas como antagonistas del receptor ccr2 y usos de las mismas en medicamentos. | |
CY1106857T1 (el) | Βενζαμιδια 4-(αμινομεθυλ)-πιπεριδινης ως 5ht4-ανταγωνιστες | |
JP2007532596A5 (es) | ||
AR065891A1 (es) | Derivados de piridina y pirimidina como antagonistas del mglur2 | |
NO20063597L (no) | Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
JP2010155827A5 (es) | ||
CA2504269A1 (en) | Piperazinyl and diazapanyl benzamides and benzthioamides | |
EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
JP2007532594A5 (es) | ||
PE20071005A1 (es) | Derivados de piperidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |